Skip to main content
. 2019 Aug 12;5(2):e001016. doi: 10.1136/rmdopen-2019-001016

Figure 1.

Figure 1

Monthly average costs 12 months before and after switch from originator to biosimilar etanercept (n=1620 patients). Black dotted vertical line illustrates time of switch. (A) Inpatient and outpatient costs, (B) prescription medication costs.